erlotinib hydrochloride has been researched along with Neoplasms, Pleural in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; De Perrot, M; Fujino, K; Hatanaka, KC; Hatanaka, Y; Hu, HP; Jin, CS; Kaga, K; Kanno, H; Kato, T; Lee, D; Matsui, Y; Matsuno, Y; Ujiie, H; Wada, H; Weersink, RA; Wilson, BC; Wu, L; Yasufuku, K; Zheng, G | 1 |
| Arai, S; Fukuda, K; Mukae, H; Nakagawa, T; Nanjo, S; Takeuchi, S; Taniguchi, H; Yamada, T; Yamaguchi, H; Yano, S | 1 |
| Fidias, P; Jackman, DM; Jänne, PA; Johnson, BE; Kindler, HL; Lucca, J; Morse, LK; Ostler, PA; Salgia, R; Yeap, BY | 1 |
| Chang, CC; Chang, HJ; Chi, KH; Hsieh, YS; Hsu, PS; Jiang, JS; Kao, SJ; Tsang, YW; Yeh, YW | 1 |
| Houwing, RH; Koster, ME; Lips, IM; Vonk, EJ | 1 |
| Chan, AB; Lam, KC; Lee, KW; Lo, AW | 1 |
| Beijnen, JH; Lankheet, NA; Malingré, MM; Schaefer-Prokop, CM; Staaks, GH; ter Heine, R; van den Bosch, RT; van den Brand, JJ; van der Westerlaken, MM | 1 |
| Altomare, DA; Borden, EC; Gandara, DR; Garland, LL; Klein-Szanto, AJ; Nagle, RB; Rankin, C; Rivkin, SE; Scott, KM; Testa, JR | 1 |
1 review(s) available for erlotinib hydrochloride and Neoplasms, Pleural
| Article | Year |
|---|---|
Fatal interstitial lung disease associated with high erlotinib and metabolite levels. A case report and a review of the literature.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Fatal Outcome; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Myocardial Infarction; Pleural Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2012 |
3 trial(s) available for erlotinib hydrochloride and Neoplasms, Pleural
| Article | Year |
|---|---|
Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Disease-Free Survival; Erlotinib Hydrochloride; Feasibility Studies; Female; Humans; Male; Mesothelioma; Middle Aged; Pleural Neoplasms; Quinazolines; Survival Rate | 2008 |
Upfront gefitinib/erlotinib treatment followed by concomitant radiotherapy for advanced lung cancer: a mono-institutional experience.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gefitinib; Heart Neoplasms; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Pleural Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2011 |
Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Male; Mesothelioma; Middle Aged; Pleural Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Treatment Outcome | 2007 |
4 other study(ies) available for erlotinib hydrochloride and Neoplasms, Pleural
| Article | Year |
|---|---|
Preclinical investigation of folate receptor-targeted nanoparticles for photodynamic therapy of malignant pleural mesothelioma.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Folate Receptor 1; Humans; Lipids; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Mice, Nude; Middle Aged; Nanoparticles; Photochemotherapy; Pleural Neoplasms; Porphyrins; Protein Kinase Inhibitors; Treatment Outcome; Xenograft Model Antitumor Assays | 2018 |
Amphiregulin triggered epidermal growth factor receptor activation confers in vivo crizotinib-resistance of EML4-ALK lung cancer and circumvention by epidermal growth factor receptor inhibitors.
Topics: Amphiregulin; Anaplastic Lymphoma Kinase; Animals; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Cell Line, Tumor; Crizotinib; Disease Models, Animal; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mice; Microtubule-Associated Proteins; Mutation; Pleural Effusion; Pleural Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Receptor Protein-Tyrosine Kinases; RNA, Small Interfering; Serine Endopeptidases; Xenograft Model Antitumor Assays | 2017 |
Erlotinib-induced rash spares previously irradiated skin.
Topics: Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Progression; Dose Fractionation, Radiation; Drug Eruptions; Erlotinib Hydrochloride; Fatal Outcome; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pleural Neoplasms; Protein Kinase Inhibitors; Quinazolines; Radiodermatitis; Radiotherapy, Adjuvant; Tomography, X-Ray Computed | 2011 |
Erlotinib in metastatic bronchopulmonary mucoepidermoid carcinoma.
Topics: Adult; Carcinoma, Mucoepidermoid; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mediastinal Neoplasms; Pleural Neoplasms; Protein Kinase Inhibitors; Quinazolines; Splenic Neoplasms | 2011 |